AzTrials
AzTrials

Liver Transplant SurgeryEXALTNCT07063940

Home-based EXercise and motivAtional Program Before and After Liver Transplantation

A study testing Home-based exercise and theory-based motivation support programme and Patient exercise advice leaflet before and after LT. in people with Liver Transplant Surgery, run by University of Birmingham at 3 sites in United Kingdom.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Liver disease is the 3rd commonest cause of death in adults of working age and liver transplantation (LT) remains the only cure for liver failure. LT exerts a huge stress on the body and mind, especially in people who are already physically and mentally frail because of their liver disease. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Liver Transplant Surgery
What is being tested?
Home-based exercise and theory-based motivation support programme and Patient exercise advice leaflet before and after LT.
Could I receive a placebo?
No, everyone receives an active treatment
How many people
269 participants
Where
3 sitesUnited Kingdom
Study dates
3 May 2022to May 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patients (aged 18 years or over)
  • Patients listed for a cadaveric, primary LT at QEUHB or the RFH
  • Being an out-patient at the time of baseline trial visit (consent)

Who cannot join

  • Patients listed for LT for any of the following reasons:
  • super-urgent LT (according to the Kings College criteria)
  • multi-organ transplantation (e.g. combined liver and kidney transplant)
  • live-related donor LT
  • re-graft LT
  • Patients with an inability to safely comply with the exercise intervention due to:
Show all 13Show fewer
  • severe hepatic encephalopathy (grade 3 or 4; or as judged by the clinical investigators)
  • oxygen-dependent hepato-pulmonary syndrome
  • Patients without liver failure, including:
  • liver cancer in the absence of cirrhosis
  • polycystic liver disease
  • rare metabolic/genetic conditions (e.g. glycogen storage disorders)
  • Refusal or lacks capacity to give informed consent to participate in the trial, at the point of study visit 1 (baseline)

Trial locations and contacts

3 sites in 1 country.

United Kingdom3 sites
  • Birmingham Clinical Trials Unit (BCTU)

    Birmingham, B15 2TT

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham

  • Royal Free Hospital

    London

Other trials in United Kingdom

About this study

Official title: Home-based EXercise and motivAtional Program Before and After Liver Transplantation: EXALT

Liver disease is the 3rd commonest cause of death in adults of working age and liver transplantation (LT) remains the only cure for liver failure. LT exerts a huge stress on the body and mind, especially in people who are already physically and mentally frail because of their liver disease. Investigators know that being physically frailty prior to surgery results in a longer hospital stay because of postoperative complications and contributes to 1 in 10 patients either dying whilst still on the waiting list or shortly after LT. Exercise is one of the most powerful medical therapies available, with numerous proven benefits to patients with diseases like diabetes, heart disease and cancer. Despite this, exercise is not currently used in patients with liver failure or recovering from LT, due to a lack of robust evidence. Exercise may have the potential to improve the lives of people with liver disease and reduce the side-effects of LT surgery. The current standard of care for NHS patients awaiting LT is an advice leaflet. Evidence-based exercise programmes around the time of transplantation do not exist. Only a few small studies have indicated that supervised, hospital-based exercise can improve physical function and quality of life. AIMS: Investigators aim to determine the effect of a home-based exercise and motivation-support programme in patients undergoing LT on their quality of life after surgery. Investigators would also like to understand if exercise results in improvements in intricate measures of physical fitness and muscle function that account for changes in quality of life, and how the motivation-support component of the intervention enhances uptake and ongoing engagement of exercise pre and post LT.

Read the detailed description

Investigators intend to perform a clinical trial, in which patients will be randomly allocated to receive either the home-based exercise/motivation support programme (intervention group) or a patient advice leaflet (control group) whilst on the LT waiting list. The intervention will begin whilst patients are on the LT waiting list and end 6 months after LT. The intervention will consist of regular strength and endurance exercises, tailored to each patient's level of fitness. During clinic visits and via telephone calls a physiotherapist will provide motivational support throughout the exercise programme. The trial will involve recruiting 266 patients over two years from two LT hospitals in England. Investigators shall assess the effectiveness of the intervention by measuring quality of life before and after the study period in both groups of patients. The intervention will be deemed effective if quality of life scores are higher with the intervention than the control group.

Being tested
Home-based exercise and theory-based motivation support programme, Patient exercise advice leaflet before and after LT.
Keywords
liver disease, quality of life, Liver transplant, Exercise and motivation
Medical subject headings
Liver Diseases, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Home-based exercise and theory-based motivation support programmeOther

    1. A remotely-monitored personalised home-based exercise programme (HBEP) and
    2. An autonomous motivation enhancement programme, known as Empowering Physio, delivered to physiotherapists to support them in delivering the HBEP.
  • Patient exercise advice leaflet before and after LT.Other

    Control

Study groups in NCT07063940
Study groupRoleWhat they receive
Control: Group 2Active comparatorPatient exercise advice leaflet before and after LT.
Receives: Other: Patient exercise advice leaflet before and after LT.
Group 1: Home-based exercise and motivation support programmeExperimentalRemotely-monitored home-based exercise and theory-based motivation support programme whilst on the LT waiting list (max. 12 months) through to 24 weeks post-LT.
Receives: Other: Home-based exercise and theory-based motivation support programme

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The physical component score (PCS) from the short form-36 version 2.0 (SF-36v2) health-related Quality of Life questionnaire

    The primary outcome measure for this trial is the PCS from the SF-36v2 health-related QoL questionnaire at 24 weeks post LT. The SF-36v2 questionnaire includes 36 questions composed of eight multi-item scales, which reflect the impact of health problems on both the physical and mental condition of the patient.(A higher score reflects better quality of life. Two summary sub-scores can be calculated which are weighted combinations of the 8 scales, one to reflect the impact on physical function (PCS) and one to reflect the impact on psychological function, known as the mental component score (MCS).Scoring of the SF-36v2 questionnaire will based on the instructions provided in the SF-36v2 user's manual.

    Measured: Baseline (visit 1, week 0) up to 24 weeks post-LT

Secondary outcomes (18)
  1. Surgical complications -Comprehensive Complication Index (CCI):

    The CCI is a well validated, reproducible tool in surgery and LT, which provides a 0-100 index (0=no complications, 100=death) using the frequency and grade (CTCAE grade) of surgical-related complications (i.e. wound dehiscence, bile leak, abdominal collections, bleeding, hepatic artery thrombosis etc).

    Measured: LT up to 24 weeks post-LT

  2. Mental Component Score (MCS) of SF-36v2 health-related QoL questionnaire

    The SF-36v2 questionnaire is a practical, reliable, and valid measure of physical and mental health that can be completed in 5 to 10 minutes. Scoring of the (MCS) SF-36v2 questionnaire is as described above for PCS SF-36v2 questionnaire.

    Measured: Baseline (visit 1, week 0) up to 24 weeks post-LT

  3. Liver Frailty Index (LFI)

    The LFI is a composite metric of three performance-based measures: hand grip strength (HGS), time to do 5 chair stands (seconds) and time holding 3 balance positions (feet side by side, semi-tandem and tandem) to objectively assess physical frailty in ambulatory patients with end-stage liver disease. The LFI score can be calculated using an on-line calculator (available at: http://liverfrailtyindex.ucsf.edu) with patient physical frailty categorised as robust, pre-frail and frail according to their index (index ≤ 3.2 (robust), 3.2-4.5 (pre-frail), >4.5 (frail)).

    Measured: Baseline (visit 1, week 0) up to 24 weeks post-LT

  4. Duke activity status index (DASI):

    The DASI is a 12 item self-reported assessment of functional capacity that requires minimal time to complete. It provides prognostic information in a variety of chronic diseases and can be used as an index of disease progression over time .

    Measured: Baseline (visit 1, week 0) up to 24 weeks post-LT

  5. Pre-LT mortality (*assessed up to day of LT)

    The date and cause (based on death certificate) of death will be recorded.

    Measured: Baseline (visit 1, week 0) up to LT or the 48 week visit.

  6. Pre-LT UKELD

    UKELD: a scoring system (using a patient's international normalized ratio (INR), serum bilirubin, creatinine and sodium) used to predict the prognosis of patients with end-stage liver disease.

    Measured: Baseline (visit 1, week 0) up to LT or the 48 week visit.

  7. Pre-LT MELD-Na

    MELD-Na Score: is a scoring system created in 2008, based on the original MELD score, but with the addition of serum sodium. The MELD-Na, largely used for prioritisation in the United States, is a better predictor of mortality than the MELD score. Patients on oral anti-coagulants (including warfarin and the new oral anti-coagulants; predicted to be <2%) will be excluded from the analysis, as their UKELD/MELD-Na will be artificially high.

    Measured: Baseline (visit 1, week 0) up to LT or the 48 week visit.

  8. Pre-LT unscheduled hospitalisations

    Unscheduled hospital admissions: The frequency and duration (days) of non-elective hospital admissions .

    Measured: Baseline (visit 1, week 0) up to LT or the 48 week visit.

  9. Post-LT length of ICU stay (hours)

    Length of ICU stay (hours)

    Measured: Between Liver transplant and immediately post-LT

  10. length of hospital stay

    length of hospital stay (days)

    Measured: Between Liver transplant and immediately post-LT

  11. Re-listing for transplant

    Re-listing for transplant will be recorded (date, reason) .

    Measured: Between Liver transplant and Visit 9 (24 weeks post liver transplant)

  12. Post-LT mortality:

    The date and cause (based on death certificate) of death will be recorded.

    Measured: Between Liver transplant and Visit 10 (48 weeks post liver transplant)

  13. Habitual physical activity levels

    Habitual (daily) levels of physical activity engagement (light, moderate and vigorous intensity) which may occur during the course of the trial will be measured using a 'blinded' wrist worn accelerometer (Actigraph GT9X). These will be worn for 14 days (24 hours/day):

    • Baseline (visit 1, week 0) to 14 days
    • 14 days before visit 2 (6 weeks), visit 3 (12 weeks) and visit 4 (24 weeks) pre-LT
    • 14 days before visit 7 (6 weeks post-LT), visit 8 (12 weeks post-LT) and visit 9 (24 weeks post-LT, end of intervention) Data captured during the 14-day periods will be analysed to quantify daily time (min/day) spent in; (1) light physical activity (1.6 - 2.9 metabolic equivalents (METS), (2) moderate physical activity (≥ 3 - 5.9 METS), (3) vigorous physical activity (≥6 METS), and sedentary time (≤1.5 METS).

    Measured: Between Baseline (visit 1, week 0) and 24 weeks post LT

  14. "Dose" of exercise completed (measure of the frequency, intensity and duration of exercise)

    Data will be analysed from the 'blinded' wrist worn accelerometer (Actigraph GT9X) to understand the intensity and duration of the exercises completed during the 14 day periods.

    Measured: Between Baseline ((visit 1, week 0) and 24 weeks post LT

  15. Adherence to HBEP (intervention arm only)

    Adherence to the HBEP will be measured using the 'blinded' wrist-worn accelerometer worn in the 14 day periods (described above). In addition, the participant will fill a self-reported exercise diary throughout the trial, which will be reviewed by the physiotherapist at each face-to-face trial visit until visit 9 (24 weeks post-LT, end of intervention). Using the diary, the physiotherapist will document how many structured HBEP sessions the participant has completed per week (maximum 5 per week).

    Measured: Between study baseline (visit 1) and 24 weeks post LT

  16. Perceptions of the health care climate (how need supportive/empowering the physiotherapist is)

    This will be measured using the Health Care Climate Questionnaire (HCCQ). The HCCQ comprises 15 items/statements which represent the patient's perceptions of the degree to which they feel their interactions with their physiotherapist (health care climate) empower them to engage in exercise (e.g. "I feel that my physiotherapist has provided me choices and options"). Patients are asked to respond to each item, indicating the extent to which they agree with each statement, on a Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree).

    Measured: Between Baseline (visit 1, week 0) and 24 weeks post LT

  17. Basic psychological need satisfaction (i.e. feelings of autonomy, relatedness, competence)

    This will be measured using the Basic Psychological Need Satisfaction in Exercise Scale (PNSE): The PNSE will be used to examine participants basic psychological need satisfaction, in relation to their exercise engagement. The PNSE comprises 18 items, capturing the three basic psychological needs of autonomy (6 items, e.g. "I feel free to exercise in my own way"), competence (6 items, e.g. "feel that I am able to complete exercises that are personally challenging") and relatedness (6 items, e.g. I feel connected to the people who I interact with while I exercise"). Participants are asked to respond to each item, indicating the degree with which they agree with each statement, on a Likert scale from 1 (false) to 6 (true).

    Measured: Between Baseline (visit 1, week 0) and 24 weeks post LT

  18. Self-determined motivation to exercise

    This will be measured using the Behavioural Regulation in Exercise Questionaire-2 (BREQ-2). The BREQ-2 will measure participant's degree of self-determined motivation to engage in exercise, by assessing their external, introjected, identified and intrinsic regulations, as well as motivation. Following the stem, "I take part in exercise" participants will be asked to respond to 19 items assessing intrinsic regulation (4 items; e.g., "because I enjoy doing this"), identified regulation (4 items; e.g., "because I value the benefits of doing this"), introjected regulation (3 items; e.g., "because I feel guilty when I am not doing this"), external regulation (4 items; e.g., "because my friends and family say I should") and motivation (4 items; e.g., "but I think doing this is a waste of time"). Participants were asked to rate their agreement with each statement on a 5-point Likert scale from 0 (not true for me) to 4 (very true for me).

    Measured: Between Baseline (visit 1, week 0) and 24 weeks post LT

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jul 2025
  2. Study start3 May 2022
  3. Primary completionNov 2025 (estimated)
  4. Study completionMay 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
269 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07063940
Sponsor's protocol ID
RG_20-065
Acronym
EXALT
Status last verified
Jul 2025
First submitted
11 Jun 2025
Last updated
14 Jul 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Home-based exercise and theory-based motivation support programme and Patient exercise advice leaflet before and after LT. in people with Liver Transplant Surgery, run by University of Birmingham at 3 sites in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 14 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The physical component score (PCS) from the short form-36 version 2.0 (SF-36v2) health-related Quality of Life questionnaire (time frame: Baseline (visit 1, week 0) up to 24 weeks post-LT). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in